EX-10.14 6 dex1014.htm DEVELOPMENT AGREEMENT *CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TRATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS DEVELOPMENT AGREEMENT BETWEEN...Development Agreement • May 5th, 2020 • California
Contract Type FiledMay 5th, 2020 JurisdictionTHIS AGREEMENT is entered into as of the 30th day of November, 2004, (“Effective Date”) by and between THRESHOLD PHARMACEUTICALS, INC., a Delaware corporation having its principal place of business at 951 Gateway Blvd., Suite 3A, South San Francisco, CA 94080, U.S.A. (“Threshold”), and MEDIBIC CO., LTD., a Japan corporation, having its head office at Daido Seimei Kasumigaseki Building 8F, 1-4-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan (“MediBIC”).
CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TRATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONSDevelopment Agreement • January 28th, 2005 • Threshold Pharmaceuticals Inc • Pharmaceutical preparations • California
Contract Type FiledJanuary 28th, 2005 Company Industry JurisdictionTHIS AGREEMENT is entered into as of the 30th day of November, 2004, (“Effective Date”) by and between THRESHOLD PHARMACEUTICALS, INC., a Delaware corporation having its principal place of business at 951 Gateway Blvd., Suite 3A, South San Francisco, CA 94080, U.S.A. (“Threshold”), and MEDIBIC CO., LTD., a Japan corporation, having its head office at Daido Seimei Kasumigaseki Building 8F, 1-4-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan (“MediBIC”).
CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TRATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONSDevelopment Agreement • December 6th, 2004 • Threshold Pharmaceuticals Inc • Pharmaceutical preparations • California
Contract Type FiledDecember 6th, 2004 Company Industry JurisdictionTHIS AGREEMENT is entered into as of the 30th day of November, 2004, (“Effective Date”) by and between THRESHOLD PHARMACEUTICALS, INC., a Delaware corporation having its principal place of business at 951 Gateway Blvd., Suite 3A, South San Francisco, CA 94080, U.S.A. (“Threshold”), and MEDIBIC CO., LTD., a Japan corporation, having its head office at Daido Seimei Kasumigaseki Building 8F, 1-4-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan (“MediBIC”).